Anti-HDV immunoglobulin M testing in hepatitis delta revisited: Correlations with disease activity and response to pegylated interferon-alpha 2a treatment
Date
2012
Authors
Mederacke, Ingmar
Yurdaydın, Cihan
Dalekos, George N.
Bremer, Birgit
Erhardt, Andreas
Çakaloğlu, Yılmaz
Yalçın, Kendal
Zeuzem, Stefan
Zachou, Kalliopi
Bozkaya, Hakan
Journal Title
Journal ISSN
Volume Title
Publisher
Int Medical
Abstract
Background: The role of anti-HDV immunoglobulin M (IgM) testing in patients receiving pegylated interferon-alpha therapy for hepatitis delta is unknown. We performed anti-HDV IgM testing in a well defined cohort of HDVinfected patients who were treated with pegylated interferon-alpha 2a plus adefovir, or either drug alone. Methods: Sera from 33 HDV-RNA-positive patients from the international HIDIT-1 trial were available for anti-HDV IgM testing (ETI-DELTA-IGMK-2 assay, DiaSorin, Saluggia, Italy) before therapy, at treatment weeks 24 and 48, and at 24 weeks after the end of treatment. Results: Anti-HDV IgM tested positive in 31 out of the 33 patients (94%) prior to treatment. HDV IgM levels correlated with histological inflammatory activity (r= 0.51, P<0.01) and were higher in patients with alanine aminotransferase and gamma-glutamyl transpeptidase levels above the median (P<0.05). Quantitative anti-HDV IgM values declined in patients responding to antiviral therapy, however anti-HDV IgM remained positive after treatment in the majority of virological responders. Conclusions: We suggest that anti-HDV IgM testing might give additional useful information to determine disease activity in hepatitis delta and to predict treatment response to antiviral therapy with type I interferons. However, determination of anti-HDV IgM can not substitute HDV RNA testing, which remains the primary virological marker for response to therapy.
Description
Keywords
Infectious diseases, Pharmacology & pharmacy, Virology, T-cell response, Virus-infection, Igm antibodies, I-interferon, Patterns, Therapy, Europe, Serum, Rna, Hbv
Citation
Mederacke, I. vd. (2012). "Anti-HDV immunoglobulin M testing in hepatitis delta revisited: Correlations with disease activity and response to pegylated interferon-alpha 2a treatment". Antiviral Therapy, 17(2), 305-312.